Antiphospholipid syndrome and the heart: A case series and literature review

Autoimmunity Reviews

Volumn 14, Issue 3, 2015, Pages 214-222

  Denas, Gentian ^a   Jose, Seema Padayattil ^a   Bracco, Alessia ^a   Zoppellaro, Giacomo ^a   Pengo, Vittorio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antiphospholipid syndrome; A 2GPI; Heart involvement; Lupus anticoagulant

Indexed keywords

CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CORONARY ARTERY; DIFFERENTIAL DIAGNOSIS; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HUMAN; ISCHEMIC HEART DISEASE; LABORATORY DIAGNOSIS; MATERNAL MORBIDITY; REVIEW; SYSTEMIC DISEASE; VALVULAR HEART DISEASE; VEIN THROMBOSIS; HEART DISEASES; IMMUNOLOGY; LUNG EMBOLISM; THROMBOSIS;

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; DIAGNOSIS, DIFFERENTIAL; HEART DISEASES; HUMANS; PULMONARY EMBOLISM; THROMBOSIS;

EID: 84921060282     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.11.003     Document Type: Review

References (99)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306.
2. de Laat H.B., Derksen R.H., Urbanus R.T., Roest M., de Groot P.G. Beta2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004, 104:3598-3602.
3. Tripodi A., de Groot P.G., Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 2011, 270:110-122.
4. Jara L.J., Medina G., Vera-Lastra O., Amigo M.C. Accelerated atherosclerosis, immune response and autoimmune rheumatic diseases. Autoimmun Rev 2006, 5:195-201.
5. Pengo V., Tripodi A., Reber G., Rand J.H., Ortel T.L., Galli M., et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, 7:1737-1740.
6. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011, 7:330-339.
7. Pengo V., Banzato A., Denas G., Jose S.P., Bison E., Hoxha A., et al. Correct laboratory approach to APS diagnosis and monitoring. Autoimmun Rev 2013, 12:832-834.
8. Pengo V., Biasiolo A., Pegoraro C., Cucchini U., Noventa F., Iliceto S. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005, 93:1147-1152.
9. Ruffatti A., Tonello M., Del Ross T., Cavazzana A., Grava C., Noventa F., et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006, 96:337-341.
10. Galli M. The antiphospholipid triangle. J Thromb Haemost 2010, 8:234-236.
11. Pengo V., Ruffatti A., Legnani C., Testa S., Fierro T., Marongiu F., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011, 118:4714-4718.
12. Roldan C.A. Valvular and coronary heart disease in systemic inflammatory diseases: Systemic Disorders in heart disease. Heart 2008, 94:1089-1101.
13. Long B.R., Leya F. The role of antiphospholipid syndrome in cardiovascular disease. Hematol Oncol Clin North Am 2008, 22:79-94. [vi-vii].
14. Cervera R. Coronary and valvular syndromes and antiphospholipid antibodies. Thromb Res 2004, 114:501-507.
15. Sitia S., Atzeni F., Sarzi-Puttini P., Di Bello V., Tomasoni L., Delfino L., et al. Cardiovascular involvement in systemic autoimmune diseases. Autoimmun Rev 2009, 8:281-286.
16. Hojnik M., George J., Ziporen L., Shoenfeld Y. Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome. Circulation 1996, 93:1579-1587.
17. Garcia-Torres R., Amigo M.C., de la Rosa A., Moron A., Reyes P.A. Valvular heart disease in primary antiphospholipid syndrome (PAPS): clinical and morphological findings. Lupus 1996, 5:56-61.
18. Cervera R. Recent advances in antiphospholipid antibody-related valvulopathies. J Autoimmun 2000, 15:123-125.
19. Nesher G., Ilany J., Rosenmann D., Abraham A.S. Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment. Semin Arthritis Rheum 1997, 27:27-35.
20. Lev S., Shoenfeld Y. Cardiac valvulopathy in the antiphospholipid syndrome. Clin Rev Allergy Immunol 2002, 23:341-348.
21. Ziporen L., Goldberg I., Arad M., Hojnik M., Ordi-Ros J., Afek A., et al. Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves. Lupus 1996, 5:196-205.
22. Amital H., Langevitz P., Levy Y., Afek A., Goldberg I., Pras M., et al. Valvular deposition of antiphospholipid antibodies in the antiphospholipid syndrome: a clue to the origin of the disease. Clin Exp Rheumatol 1999, 17:99-102.
23. Afek A., Shoenfeld Y., Manor R., Goldberg I., Ziporen L., George J., et al. Increased endothelial cell expression of alpha3beta1 integrin in cardiac valvulopathy in the primary (Hughes) and secondary antiphospholipid syndrome. Lupus 1999, 8:502-507.
24. Turiel M., Muzzupappa S., Gottardi B., Crema C., Sarzi-Puttini P., Rossi E. Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography. Lupus 2000, 9:406-412.
25. Tenedios F., Erkan D., Lockshin M.D. Cardiac manifestations in the antiphospholipid syndrome. Rheum Dis Clin North Am 2006, 32:491-507.
26. Silbiger J.J. The cardiac manifestations of antiphospholipid syndrome and their echocardiographic recognition. J Am Soc Echocardiogr 2009, 22:1100-1108. [quiz 1195].
27. Gorki H., Malinovski V., Stanbridge R.D. The antiphospholipid syndrome and heart valve surgery. Eur J Cardiothorac Surg 2008, 33:168-181.
28. Qaddoura F., Connolly H., Grogan M., Orszulak T.A., Schaff H.V., Chandrasekaran K., et al. Valve morphology in antiphospholipid antibody syndrome: echocardiographic features. Echocardiography 2005, 22:255-259.
29. O'Neill D., Magaldi J., Dobkins D., Greco T. Dissolution of intracardiac mass lesions in the primary antiphospholipid antibody syndrome. Arch Intern Med 1995, 155:325-327.
30. Agirbasli M.A., Hansen D.E., Byrd B.F. Resolution of vegetations with anticoagulation after myocardial infarction in primary antiphospholipid syndrome. J Am Soc Echocardiogr 1997, 10:877-880.
31. Espinola-Zavaleta N., Vargas-Barron J., Colmenares-Galvis T., Cruz-Cruz F., Romero-Cardenas A., Keirns C., et al. Echocardiographic evaluation of patients with primary antiphospholipid syndrome. Am Heart J 1999, 137:973-978.
32. Koniari I., Siminelakis S.N., Baikoussis N.G., Papadopoulos G., Goudevenos J., Apostolakis E. Antiphospholipid syndrome; its implication in cardiovascular diseases: a review. J Cardiothorac Surg 2010, 5:101.
33. Erdogan D., Goren M.T., Diz-Kucukkaya R., Inanc M. Assessment of cardiac structure and left atrial appendage functions in primary antiphospholipid syndrome: a transesophageal echocardiographic study. Stroke 2005, 36:592-596.
34. Brenner B., Blumenfeld Z., Markiewicz W., Reisner S.A. Cardiac involvement in patients with primary antiphospholipid syndrome. J Am Coll Cardiol 1991, 18:931-936.
35. Krause I., Lev S., Fraser A., Blank M., Lorber M., Stojanovich L., et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis 2005, 64:1490-1493.
36. Zavaleta N.E., Montes R.M., Soto M.E., Vanzzini N.A., Amigo M.C. Primary antiphospholipid syndrome: a 5-year transesophageal echocardiographic followup study. J Rheumatol 2004, 31:2402-2407.
37. Lockshin M., Tenedios F., Petri M., McCarty G., Forastiero R., Krilis S., et al. Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report. Lupus 2003, 12:518-523.
38. Shahian D.M., Labib S.B., Schneebaum A.B. Etiology and management of chronic valve disease in antiphospholipid antibody syndrome and systemic lupus erythematosus. J Card Surg 1995, 10:133-139.
39. Habib G., Hoen B., Tornos P., Thuny F., Prendergast B., Vilacosta I., et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009, 30:2369-2413.
40. Habib G., Badano L., Tribouilloy C., Vilacosta I., Zamorano J.L., Galderisi M., et al. Recommendations for the practice of echocardiography in infective endocarditis. Eur J Echocardiogr 2010, 11:202-219.
41. Marijon E., Celermajer D.S., Tafflet M., El-Haou S., Jani D.N., Ferreira B., et al. Rheumatic heart disease screening by echocardiography: the inadequacy of World Health Organization criteria for optimizing the diagnosis of subclinical disease. Circulation 2009, 120:663-668.
42. Colli A., Mestres C.A., Espinosa G., Plasin M.A., Pomar J.L., Font J., et al. Heart valve surgery in patients with the antiphospholipid syndrome: analysis of a series of nine cases. Eur J Cardiothorac Surg 2010, 37:154-158.
43. Cervera R., Boffa M.C., Khamashta M.A., Hughes G.R. The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe. Lupus 2009, 18:889-893.
44. Shoenfeld Y., Gerli R., Doria A., Matsuura E., Cerinic M.M., Ronda N., et al. Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005, 112:3337-3347.
45. Jara L.J., Medina G., Vera-Lastra O., Shoenfeld Y. Atherosclerosis and antiphospholipid syndrome. Clin Rev Allergy Immunol 2003, 25:79-88.
46. Artenjak A., Lakota K., Frank M., Cucnik S., Rozman B., Bozic B., et al. Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review. Autoimmun Rev 2012, 11:873-882.
47. Shoenfeld Y., Harats D., George J. Atherosclerosis and the antiphospholipid syndrome: a link unravelled?. Lupus 1998, 7(Suppl. 2):S140-S143.
48. Matsuura E., Lopez L.R. Are oxidized LDL/beta2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis?. Clin Dev Immunol 2004, 11:103-111.
49. Matsuura E., Kobayashi K., Inoue K., Lopez L.R., Shoenfeld Y. Oxidized LDL/beta2-glycoprotein I complexes: new aspects in atherosclerosis. Lupus 2005, 14:736-741.
50. Rhew E.Y., Ramsey-Goldman R. Premature atherosclerotic disease in systemic lupus erythematosus-role of inflammatory mechanisms. Autoimmun Rev 2006, 5:101-105.
51. Matsuura E., Hughes G.R., Khamashta M.A. Oxidation of LDL and its clinical implication. Autoimmun Rev 2008, 7:558-566.
52. Kobayashi K., Matsuura E., Liu Q., Furukawa J., Kaihara K., Inagaki J., et al. A specific ligand for beta(2)-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages. J Lipid Res 2001, 42:697-709.
53. Kobayashi K., Kishi M., Atsumi T., Bertolaccini M.L., Makino H., Sakairi N., et al. Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 2003, 44:716-726.
54. Soltesz P., Szekanecz Z., Kiss E., Shoenfeld Y. Cardiac manifestations in antiphospholipid syndrome. Autoimmun Rev 2007, 6:379-386.
55. Medina G., Casaos D., Jara L.J., Vera-Lastra O., Fuentes M., Barile L., et al. Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 2003, 62:607-610.
56. Grobbee D.E., Bots M.L. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994, 236:567-573.
57. Wahl D.G., Bounameaux H., de Moerloose P., Sarasin F.P. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000, 160:2042-2048.
58. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005, 45:89-118.
59. Meroni P.L., Borghi M.O., Raschi E., Ventura D., Sarzi Puttini P.C., Atzeni F., et al. Inflammatory response and the endothelium. Thromb Res 2004, 114:329-334.
60. Bruce I.N. Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin?. Best Pract Res Clin Rheumatol 2005, 19:823-838.
61. Cervera R., Piette J.C., Font J., Khamashta M.A., Shoenfeld Y., Camps M.T., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002, 46:1019-1027.
62. Takeuchi S., Obayashi T., Toyama J. Primary antiphospholipid syndrome with acute myocardial infarction recanalised by PTCA. Heart 1998, 79:96-98.
63. Biceroglu S., Ildizli Demirbas M., Karaca M., Yalcin M., Yilmaz H. Acute thrombotic occlusion of right coronary and left circumflex coronary arteries in a patient with antiphospholipid syndrome: successful stent implantation. Case Rep Med 2010, 2010:198594.
64. Jankowski M., Dudek D., Dubiel J.S., Musial J. Successful coronary stent implantation in a patient with primary antiphospholipid syndrome. Blood Coagul Fibrinolysis 1998, 9:753-756.
65. Su H.M., Lee K.T., Chu C.S., Sheu S.H., Lai W.T. Acute thrombosis after elective direct intracoronary stenting in primary antiphospholipid syndrome: a case report. Kaohsiung J Med Sci 2003, 19:177-182.
66. Weissman A., Coplan N.L. Antiphospholipid antibody syndrome and acute stent thrombosis. Rev Cardiovasc Med 2006, 7:244-246.
67. Perl L., Netzer A., Rechavia E., Bental T., Assali A., Codner P., et al. Long-term outcome of patients with antiphospholipid syndrome who undergo percutaneous coronary intervention. Cardiology 2012, 122:76-82.
68. Denas G., Padayattil Jose S., Gresele P., Erba N., Testa S., De Micheli V., et al. Major bleeding in patients undergoing PCI and triple or dual antithrombotic therapy: a parallel-cohort study. J Thromb Thrombolysis 2013, 35:178-184.
69. Crowther M.A., Ginsberg J.S., Julian J., Denburg J., Hirsh J., Douketis J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003, 349:1133-1138.
70. Finazzi G., Marchioli R., Brancaccio V., Schinco P., Wisloff F., Musial J., et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005, 3:848-853.
71. Hegde V.A., Vivas Y., Shah H., Haybron D., Srinivasan V., Dua A., et al. Cardiovascular surgical outcomes in patients with the antiphospholipid syndrome-a case-series. Heart Lung Circ 2007, 16:423-427.
72. Moss A.J., Zareba W., Hall W.J., Klein H., Wilber D.J., Cannom D.S., et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002, 346:877-883.
73. Ullah W., Chambers J.B., Hunt B.J., Blauth C., Rinaldi C.A. Massive thrombi on an implantable cardioverter-defibrillator lead in a patient with the antiphospholipid syndrome. Europace 2011, 13:1205-1206.
74. Lauwerys B.R., Lambert M., Vanoverschelde J.L., Cosyns J.P., Houssiau F.A. Myocardial microangiopathy associated with antiphospholipid antibodies. Lupus 2001, 10:123-125.
75. Azeem T., Vassallo M., Samani N.J. Images in cardiology. Endomyocardial fibrosis associated with antiphospholipid syndrome. Heart 2000, 84:156.
76. Murphy J.J., Leach I.H. Findings at necropsy in the heart of a patient with anticardiolipin syndrome. Br Heart J 1989, 62:61-64.
77. Sacre K., Brihaye B., Hyafil F., Serfaty J.M., Escoubet B., Zennaro M.C., et al. Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study. Arthritis Rheum 2010, 62:2093-2100.
78. Brey R.L., Abbott R.D., Curb J.D., Sharp D.S., Ross G.W., Stallworth C.L., et al. Beta(2)-glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke 2001, 32:1701-1706.
79. Bili A., Moss A.J., Francis C.W., Zareba W., Watelet L.F., Sanz I. Anticardiolipin antibodies and recurrent coronary events: a prospective study of 1150 patients. Thrombogenic Factors, and Recurrent Coronary Events Investigators. Circulation 2000, 102:1258-1263.
80. Iverson G.M., von Muhlen C.A., Staub H.L., Lassen A.J., Binder W., Norman G.L. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI. J Autoimmun 2006, 27:266-271.
81. Greco T.P., Conti-Kelly A.M., Greco T., Doyle R., Matsuura E., Anthony J.R., et al. Newer antiphospholipid antibodies predict adverse outcomes in patients with acute coronary syndrome. Am J Clin Pathol 2009, 132:613-620.
82. Greisman S.G., Thayaparan R.S., Godwin T.A., Lockshin M.D. Occlusive vasculopathy in systemic lupus erythematosus. Association with anticardiolipin antibody. Arch Intern Med 1991, 151:389-392.
83. Al-Kiyumi W.A., Venugopalan P. Antiphospholipid syndrome presenting as dilated cardiomyopathy in an 11-year-old boy. Acta Cardiol 2003, 58:359-361.
84. Paran D., Caspi D., Levartovsky D., Elkayam O., Kaufman I., Litinsky I., et al. Cardiac dysfunction in patients with systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 2007, 66:506-510.
85. Laskin C.A., Clark C.A., Spitzer K.A. Antiphospholipid syndrome in systemic lupus erythematosus: is the whole greater than the sum of its parts?. Rheum Dis Clin North Am 2005, 31:255-272. [vi].
86. Tektonidou M.G., Ioannidis J.P., Moyssakis I., Boki K.A., Vassiliou V., Vlachoyiannopoulos P.G., et al. Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome. Ann Rheum Dis 2001, 60:43-48.
87. Kaplan S.D., Chartash E.K., Pizzarello R.A., Furie R.A. Cardiac manifestations of the antiphospholipid syndrome. Am Heart J 1992, 124:1331-1338.
88. Coudray N., de Zuttere D., Bletry O., Piette J.C., Wechsler B., Godeau P., et al. M mode and Doppler echocardiographic assessment of left ventricular diastolic function in primary antiphospholipid syndrome. Br Heart J 1995, 74:531-535.
89. Bidani A.K., Roberts J.L., Schwartz M.M., Lewis E.J. Immunopathology of cardiac lesions in fatal systemic lupus erythematosus. Am J Med 1980, 69:849-858.
90. Nihoyannopoulos P., Gomez P.M., Joshi J., Loizou S., Walport M.J., Oakley C.M. Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies. Circulation 1990, 82:369-375.
91. Pengo V., Biasiolo A., Marson P., De Silvestro G., Agostini C., Livi U. Immunosuppressive treatment in a heart transplantation candidate with antiphospholipid syndrome. Clin Rheumatol 1996, 15:504-507.
92. Asherson R.A. The catastrophic antiphospholipid (Asherson's) syndrome. Autoimmun Rev 2006, 6:64-67.
93. Lang I.M. Chronic thromboembolic pulmonary hypertension-not so rare after all. N Engl J Med 2004, 350:2236-2238.
94. Vianna J.L., Khamashta M.A., Ordi-Ros J., Font J., Cervera R., Lopez-Soto A., et al. Comparison of the primary and secondary antiphospholipid syndrome: a European Multicenter Study of 114 patients. Am J Med 1994, 96:3-9.
95. Brucato A., Baudo F., Barberis M., Redaelli R., Casadei G., Allegri F., et al. Pulmonary hypertension secondary to thrombosis of the pulmonary vessels in a patient with the primary antiphospholipid syndrome. J Rheumatol 1994, 21:942-944.
96. Chaouat A., Weitzenblum E., Higenbottam T. The role of thrombosis in severe pulmonary hypertension. Eur Respir J 1996, 9:356-363.
97. Atsumi T., Khamashta M.A., Haworth R.S., Brooks G., Amengual O., Ichikawa K., et al. Arterial disease and thrombosis in the antiphospholipid syndrome: a pathogenic role for endothelin 1. Arthritis Rheum 1998, 41:800-807.
98. Espinosa G., Cervera R., Font J., Asherson R.A. The lung in the antiphospholipid syndrome. Ann Rheum Dis 2002, 61:195-198.
99. Ghofrani H.A., D'Armini A.M., Grimminger F., Hoeper M.M., Jansa P., Kim N.H., et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013, 369:319-329.